CRISPR-Cas12b enables a highly efficient attack on HIV proviral DNA in T cell cultures
The novel endonuclease Cas12b was engineered for targeted genome editing in mammalian cells and is a promising tool for certain applications because of its small size, high sequence specificity and ability to generate relatively large deletions. We previously reported inhibition of the human immunod...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/405699 |
| Acceso en línea: | http://hdl.handle.net/10261/405699 https://api.elsevier.com/content/abstract/scopus_id/85163454716 |
| Access Level: | acceso abierto |
| Palabra clave: | Antiviral CRISPR-Cas12b HIV cure Lentiviral vector (LV) |
| Sumario: | The novel endonuclease Cas12b was engineered for targeted genome editing in mammalian cells and is a promising tool for certain applications because of its small size, high sequence specificity and ability to generate relatively large deletions. We previously reported inhibition of the human immunodeficiency virus (HIV) in cell culture infections upon attack of the integrated viral DNA genome by spCas9 and Cas12a. |
|---|